Preclinical data at the EuroMAbNet Annual Meeting

RNS Number : 3799A

Scancell Holdings Plc

23 September 2022

 

23 September 2022

Scancell Holdings plc

("Scancell" or the "Company")

Scancell to present preclinical data on proprietary GlyMab ^® and AvidiMab ^®

  antibody platforms at the EuroMAbNet 12^th Annual Meeting

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces it will present two posters today at the EuroMAbNet 12^th Annual Meeting, taking place in Hamburg, Germany, between 22-24 September 2022.

The poster entitled "Unlocking the unique potential of AvidiMab^®  in fighting cancer" will highlight new data on the Company's AvidiMab ® and GlyMab ® technologies. Scancell has generated certain anti-glycan monoclonal antibodies (GlyMab ® ) that the Company believes have potential as cancer therapies. These GlyMab ® candidates were subsequently avidity-enhanced, leading to heightened anti- tumour activity in vivo, by applying Scancell's AvidiMab^®  platform, a proprietary technology for engineering the Fc region of antibodies. The Company compared the interaction of the avidity enhanced CD40-targeted GlyMab^® and a non-enhanced antibody with CD40, a tumour necrosis factor receptor (TNFR) superfamily member which plays a critical role in B and T cell immunobiology. The AvidiMab^® modified antibody showed superior CD40 binding coinciding with improved B cell expansion compared with the non-enhanced antibody.

In the poster entitled "GlyMabs, glycome-targeting monoclonal antibodies for cancer therapy", Scancell outlines the enhanced targeting and binding specifics for candidates created from the GlyMab ® technology. The four humanised monoclonal antibodies (mAbs) targeting glycans on lipids and/or proteins include candidates SC129, SC88, SC134 and SC27. The research shows that the Company's GlyMab^® candidates are highly specific for targets found in a broad range of cancers, making them viable candidates for cancer therapeutics.

Copies of the poster will be available on Scancell's website following the conference at: https://www.scancell.co.uk/antibody-publications

Prof Lindy Durrant, Chief Executive Officer, Scancell , commented: "Our proprietary antibody platforms leverage our skills and knowledge in immunology and we are excited about the future potential they give in creating truly differentiated product candidates for the treatment of certain types of cancer. The preclinical data being presented at EuroMAbNet illustrates the versatility and specificity of our platforms in generating novel antibody drug candidates using our GlyMab ® technology and enhancing their anti-cancer potential with AvidiMab ®. "

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).

For further information, please contact:
Scancell Holdings plc	[phone]
Dr John Chiplin, Executive Chairman
Professor Lindy Durrant, CEO
Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker)	[phone]
Freddy Crossley/Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)
Stifel Nicolaus Europe Limited (Joint Broker)	[phone]
Nicholas Moore/ Samira Essebiyea/William Palmer-Brown (Healthcare Investment Banking)
Nick Adams/Nick Harland (Corporate Broking)
FTI Consulting	[phone]
Simon Conway/Rob Winder/Alex Davis

About Scancell

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope ^® and ImmunoBody ^® for vaccines and GlyMab^® and AvidiMab ^® for antibodies.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope ^® and ImmunoBody ^® ) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab^®) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab ^® ).

For further information about Scancell, please visit: https://www.scancell.co.uk/

 

END

 

 

MSCSEWESEEESEDU